SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Arthur Ashe

PatientArthur Ashe
Date of birth1980-07-10
IdentifiersMRN HR-ML013-SYN; SSN (made up) 000-13-6620
Document date2026-10-19
AuthorVivian Tolliver, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Nine-month HIV review: decision about stopping toxoplasmosis maintenance therapy. [S]

History of Present Illness

Mr. Ashe returns nine months after his first visit, about thirteen months after starting antiretroviral therapy. He has missed no doses and has had no headache, weakness, seizure, rash, fever, or chest pain. His colonoscopy appointment is next month. He has read the result of the syphilis test from the preventive visit, which was sent to him by secure message. He has thought about anal cancer screening and would like to have it at his next visit. Today's blood tests were drawn this morning. [S]

ElementDetail
AdherenceNo missed doses
SymptomsNone
ScreeningColonoscopy booked; anal cancer screening chosen for the next visit

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; weight stable
CardiovascularNegativeNo chest pain
NeurologicalNegativeNo headache, seizure, or weakness
PsychiatricNegativeMood good; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesiumOne tablet by mouth once dailyOral route2025-09-25activeS
Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intakeThree tablets by mouth daily after a 200 mg loading doseOral route2025-09-11 to 2025-10-23completedS
Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intakeThree tablets by mouth every 6 hoursOral route2025-09-11 to 2025-10-23completedS
Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intakeTwo tablets by mouth dailyOral route2025-09-11 to 2025-10-23completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2025-10-23 to 2026-10-19completedS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2016-07-31activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2016-08-01activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route2016-08-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-19Body height185cmS
2026-10-19Body weight75kgS
2026-10-19Body mass index (BMI) [Ratio]21.9kg/m2S
2026-10-19Systolic blood pressure120mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate66/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-19HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
2026-10-19CD3+CD4+ (T4 helper) cells [#/volume] in Blood318/uL500-1500 /uLLowS
2026-10-19Leukocytes [#/volume] in Blood by Automated count510*3/uL4-11 10*3/uLNormalS
2026-10-19Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
2026-10-19Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-10-19Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-10-19Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-19Creatinine [Mass/volume] in Serum or Plasma1.12mg/dL0.74-1.35 mg/dLNormalS
2026-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M82mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-19Glucose [Mass/volume] in Serum or Plasma91mg/dL70-99 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 75.0 kg, blood pressure 120/74
MouthNo thrush
NeurologicalNo focal deficit; strength equal on both sides

Problems

ProblemClinical statusVerificationCodeProvenance
HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infectionactiveconfirmed B20S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled.
Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapyactiveconfirmed B58.2S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass.
Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operationsactiveconfirmed I25.10S — Synthetic modern diagnosis; the history remains D.
Old myocardial infarction at age 36activeconfirmed I25.2S — Synthetic coded history of the documented 1979 heart attack.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHIV-1 viral load4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 monthsCompleted todayNot detected (below 20 copies/mL), the third undetectable result
LaboratoryCD4 countEvery 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ARTCompleted today318 cells/uL, above 200 for more than six months
Medication safetyART adherence and drug-interaction review (antacids, calcium, iron, new medicines)Every visitCompleted todayNo missed doses; no interacting medicines
LaboratoryComplete blood countEvery 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ARTCompleted todayHemoglobin 14.1 g/dL, white cells 5.0, platelets 236
LaboratoryPotassium, creatinine, and eGFR1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 monthsCompleted todayPotassium 4.5 mmol/L, creatinine 1.12 mg/dL, eGFR 82
LaboratoryUrine albumin-to-creatinine ratio on tenofovirAt the start of tenofovir and yearlyUp to dateNormal three months ago; next in one year
LaboratoryALTEvery 6 months on ART; with symptoms on a statinDueALT 27 U/L six months ago; with the lipid panel at the next visit
Medication safetyToxoplasma maintenance therapy and stopping criteriaContinue until CD4 above 200 for more than 6 months on ART with a suppressed viral loadCompleted todayCriteria met; trimethoprim-sulfamethoxazole stopped today; restart if CD4 falls below 200
Medication safetyPneumocystis prophylaxisWhile CD4 below 200; stop after more than 3 months above 200Completed todayCD4 above 200 for more than three months; prophylaxis stops with the maintenance dose
ExaminationNeurological check: headache, seizure, weakness, and right-hand strengthEvery visitCompleted todayNo symptoms; same-day review if any develop
LaboratorySyphilis screenYearlyUp to dateDrawn at the preventive visit; result reviewed with him; next in one year
Self-managementInfluenza and COVID-19 vaccinesEach autumnCompleted todayInactivated influenza vaccine and COVID-19 vaccine given today
Self-managementPsychosocial support, disclosure on his terms, and U=U counselingEvery visitCompleted todayWell supported; disclosure remains his decision
SurveyDepression screen (PHQ-9 or PHQ-2)At intake, at six months, and yearlyUp to datePHQ-2 0 two months ago
ExaminationBlood pressure (goal below 130/80)Every visitCompleted today120/74 mmHg
ExaminationWeight, BMI, and physical activityEvery visitCompleted today75.0 kg, BMI 21.9; stable
Self-managementTobacco useEvery visitCompleted todayNever used tobacco
Medication safetyCoronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibeEvery visitCompleted todayTaking all three
Self-managementAngina review and chest-pain planEvery visitCompleted todayNo angina
LaboratoryLipid panel4 to 12 weeks after a change, then every 3 to 12 months; yearly when stableDueYearly panel at the next visit
ImagingStress testing, coronary imaging, or echocardiographyOnly with new or worsening symptoms; routine surveillance not recommendedNot indicatedNo symptoms

Goal progress:

Immunizations given today: Influenza vaccine, 2026-2027 season; COVID-19 vaccine, 2026-2027 formula [S]

Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)

Follow-up: HIV review in three months with viral load, CD4 count, lipid panel, ALT, and anal cancer screening. Colonoscopy next month. Same-day visit for headache, weakness, seizure, or fever. [S]